艾美捷科技代理Helvetica Health Care品牌全系列产品

Helvetica Health Care是一家位于瑞士日内瓦的医疗保健公司，致力于通过创新的产品和技术来管理健康和提高生活质量。作为瑞士生物技术协会的成员，Helvetica Health Care通过了ISO 13485认证，在质量和创新方面坚持最高标准。涵盖各种质量控制和验证面板，适用于不同的分子测试平台和检测。这些产品有多种规格，可用于单一或多种分析物的检测，帮助实验室监控测试性能，确保测试的准确性和可靠性。其质量控制和验证组合可根据产品配置、填充量和分析物浓度进行定制，满足不同平台的需求。

▎Helvetica Health Care产品线

Helvetica Health Care公司的产品涵盖：抗体、生命科学产品、血液分离产品、临床/诊断样本、质控品与标准品、分子生物学产品、细胞因子与生长因子、ELISA试剂盒/Western印迹相关产品、微生物、氧化应激产品、诊断产品以及人血浆制品。

▎Helvetica Health Care部分产品列表

SurModics公司成立于1979年，拥有30多年的临床诊断、生物医药、科研产品研发和开发经验，是体外诊断技术的领先品牌。可提供多种产品，主要包括蛋白稳定剂、封闭剂、缓冲剂、比色底物及化学发光底物、和抗原、抗体等。

Surmodics is the global leader in surface modification technologies for vascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) tests and microarrays. Following two acquisitions of Creagh Medical and NorMedix – recognized innovators in balloon catheters and delivery systems – we have combined capabilities in proprietary surface technologies, as well as device design, development and manufacturing that enable us to significantly increase the value we offer our medical device customers. We are focused on developing highly differentiated, total vascular device solutions to the most demanding clinical challenges. The company’s R&D pipeline is rich with novel innovations within the field of vascular medicine. Even as we expand our capabilities, our mission remains to improve the detection and treatment of disease.

Surmodics公司主要产品：

（1）蛋白稳定剂/封闭剂

免疫检测稳定剂（微量滴定板、乳胶小珠、磁珠）；微阵列芯片稳定剂； 封闭剂；结合物稳定剂（AP,HRP）；无BSA稳定剂；稳定剂包：包含免疫检测稳定剂、结合物稳定剂、无BSA稳定剂、可选择稳定剂各25ml。

（2）BioFX底物/终止剂

比色HRP底物、比色AP底物、化学发光HRP底物、化学发光AP底物、TMB底物、ABTS和pNPP底物。

（3）稀释液/缓冲液/IHC试剂/附属试剂

SurModics提供ELISA稀释液、清洗液、免疫组化试剂。

（4）DIARECT自身免疫和免疫疾病抗原

DIARECT自勉和免疫疾病抗原的质量和敏感性都经过校验。主要包括：ANCN相关疾病、自勉型肝炎和肝脏疾病、肾炎综合症、甲状腺自勉疾病、血栓栓塞综合症、莱姆病、肠炎、胃肠腹腔疾病、细小病毒等。

（5）BioFX抗体和链酶亲和素

SurModics IVD为免疫印迹、免疫组化、ELISpot、RIA、微阵列应用提供十种不同物种和六种宿主二抗。

（6）微阵列芯片

微阵列芯片通过共价键链接RNA、DNA和蛋白，使用方便，兼容性好，适用于大部分阵列和扫描设备。

更多详情请联系 

艾美捷科技有限公司

全国服务热线：400-6800-868

邮箱：sales@amyjet.com

网站：www.amyjet.com

Dendritics公司主要关注人类树突状细胞，希望找到能够促使CD34+造血前体细胞转化为树突状细胞（在GM-CSF和TNF-alpha存在的情况下）的细胞因子。在1992-2005年间，大量的研究使得研究者对人类树突状细胞的产生、细胞通路、C-type凝集素受体的功能及Toll-like受体的活性有了更深的理解。

DENDRITICS was started in 2005 by former members of SCHERING PLOUGH Laboratory for Immunological Research (LIR) in Dardilly, France. From their long experience at LIR, the team members of DENDRITICS have gathered complementary scientific and technological knowledge in different areas of immunology. The initial focus of LIR was in the biology of B lymphocytes, elaboration of human monoclonal antibodies, and in cytokine discovery (IL-3, IL-4, IL-7, IL-10, IL-17, GM-CSF) together with our colleagues of DNAX Research Institute in Palo Alto, California.

Our interest in cytokines led to the finding that human dendritic cells (DCs) could be generated in vitro from CD34+ hematopoietic progenitors cultured in the presence of GM-CSF and TNF-alpha.

The period from 1992 to 2005 saw the specialization of LIR in DC biology and was fuelled by a large-scale effort to discover and study the function of genes specifically expressed by these cells. This program led to a number of findings that contributed in particular to understanding the heterogeneity of DCs, the pathways regulating DC migration, the function of C-type lectin receptors in DCs and the activity of Toll-like receptors in DCs. Many novel genes were discovered through screening of cDNA libraries or through monoclonal antibodies raised against DCs.

更多详情请联系 

艾美捷科技有限公司

全国服务热线：400-6800-868

邮箱：sales@amyjet.com

网站：www.amyjet.com